Formulary guidance and transparency from P&T to point of care


Reality Check on Bipolar Disorder

Market access for bipolar disorder treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 23% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: A new brand drug, Allergan plc’s Vraylar (cariprazine), for bipolar disorder will have little impact on how health plans cover these medications, experts say. Health plans will continue to encourage the use of less expensive generic bipolar drugs
  • Key Findings: Coverage is primarily under the pharmacy benefit, but medical coverage
    is available for some medications. Coverage is restricted for most brand-name products

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.